Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006228 · ClinicalTrials.gov registry record · Phase 2

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

A Phase 2 study of HER2-positive Breast Cancer and Stage IV Breast Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
37
Enrollment target
1
Study location

NCT00006228 is a Phase 2 study of HER2-positive Breast Cancer and Stage IV Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 37 participants, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006228, a Phase 2 study of HER2-positive Breast Cancer and Stage IV Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill breast cancer cells. Phase II trial to study the effectiveness of trastuzumab plus interleukin-2 in treating patients who have metastatic breast cancer that has not responded to previous trastuzumab therapy.

Conditions Studied

HER2-positive Breast Cancer Stage IV Breast Cancer Recurrent Breast Cancer Male Breast Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER pharmacological study
  • BIOLOGICAL trastuzumab
  • BIOLOGICAL aldesleukin

Study Locations (1)

Ohio

  • Ohio State University Medical Center - Columbus

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2000-07
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00006228

The ClinicalTrials.gov registry entry for NCT00006228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (85% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00006228 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00006228 about?

NCT00006228 is a clinical study titled "Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer". Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill breast cancer cells. Phase II trial to study the effectiveness of trastuzum...

What is the current status of trial NCT00006228?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2000-07.

What conditions does trial NCT00006228 study?

This clinical trial studies the following conditions: HER2-positive Breast Cancer, Stage IV Breast Cancer, Recurrent Breast Cancer, Male Breast Cancer.

What interventions are being tested in trial NCT00006228?

The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), trastuzumab (BIOLOGICAL), aldesleukin (BIOLOGICAL).

Who is sponsoring clinical trial NCT00006228?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006228 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HER2-positive Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HER2-positive Breast Cancer

All registered trials for this condition

Stage IV Breast Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.